FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20549	
------------------------	--

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Martin Samuel Bates					2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]									(Ch	eck all appli Directo	cable)	ig Person(s) to Iss 10% Ov Other (s		wner
(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD						3. Date of Earliest Transaction (Month/Day/Year) 12/23/2021									X Officer (give title Officer (below) below) SVP and CFO				peony
(Street)			08827		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Application) X Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S	tate)	(Zip)												Perso	n			
		Tab	le I - No	n-Deriv	ative	Se	curit	ies Ac	quired	, Dis	sposed (of, or	Ben	eficial	ly Owned	t			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code (5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							, ,		Code	v	Amount	(A (D	A) or D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock			12/23	/2021	2021			М		3,250)	A	\$9.016	55 30	0,128		D	
Common	Common Stock			12/23	23/2021				М		3,750	3,750 A		\$2.78	33	,878	D		
Common	Stock			12/23	/2021				S ⁽¹⁾		9,5000	(1)	D	\$42	24	24,378 D			
		Т	able II -								osed of converti				Owned				•
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Executio if any (Month/D	n Date,	4. Transac Code (II 8)		5. Number of		6. Date Exerci Expiration Da (Month/Day/Yo		е	7. Title and Amount of Securities Underlying Derivative (Instr. 3 and			8. Price of Derivative Security (Instr. 5)		re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	1	Amount or Number of Shares					
Incentive Stock Option (Right to Buy)	\$9.0165	12/23/2021			М			3,250	(2)		06/13/2028	Comm		3,250	\$0.00	9,530		D	
Incentive Stock Option (Right to	\$2.78	12/23/2021			М			3,750	(3)		06/19/2029	Comm		3,750	\$0.00	24,421	1	D	

Explanation of Responses:

- 1. The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on August 12, 2021.
- $2.\ 25\%\ vested\ on\ June\ 13,\ 2019\ and\ the\ remainder\ vest\ quarterly\ (in\ equal\ amounts)\ over\ the\ subsequent\ 12\ quarters.$
- 3. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

/s/ Anthony S. Marucci, attorney in fact for Samuel

12/28/2021

Bates Martin

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.